Transdermal administration method of protein or peptide drug and its administration device thereof
First Claim
Patent Images
1. An integration-type transdermal administration device of a patch-type which may be attached to the skin comprising the following:
- A) solvent reservoir (2) for ionizing solvent and polyelectrolyte, injected from the outside through a solvent inlet (7),B) drug reservoir (3) comprising drug immersed water-swellable polymer located opposite from the solvent inlet such that the solvent reservoir (2) is interposed between the drug reservoir and the inlet, with a lower portion support (5) made of non-woven fabric, including plural skin needles (4) vertically dispersed in a fixed state on said support and said support (5) is interposed between the drug reservoir and the skin needles,C) stacking-structural adhesive layer(6) formed around the supporter of the drug reservoir.
1 Assignment
0 Petitions
Accused Products
Abstract
A transdermal administration method for protein or peptide drug that contacting and ionizing a protein or peptide drug immersed in hydrophilic polymer with ionizing solvent composition, and forming the drug pathway on epidermis by plural skin needles or treating the skin by a razor, and transferring the above ionized drug into the skin by electric force.
516 Citations
19 Claims
-
1. An integration-type transdermal administration device of a patch-type which may be attached to the skin comprising the following:
-
A) solvent reservoir (2) for ionizing solvent and polyelectrolyte, injected from the outside through a solvent inlet (7), B) drug reservoir (3) comprising drug immersed water-swellable polymer located opposite from the solvent inlet such that the solvent reservoir (2) is interposed between the drug reservoir and the inlet, with a lower portion support (5) made of non-woven fabric, including plural skin needles (4) vertically dispersed in a fixed state on said support and said support (5) is interposed between the drug reservoir and the skin needles, C) stacking-structural adhesive layer(6) formed around the supporter of the drug reservoir. - View Dependent Claims (2, 3, 4, 5, 6)
-
-
7. A separation-type transdermal administration kit of the patch-type which may be attached to the skin comprising the following:
-
a) electrode (11) located uppermost and furthest from the place of skin attachment; b) solvent reservoir (12) for ionizing solvent and polyelectrolyte located below the electrode (11); c) semipermeable membrane (18) which may have a molecular weight cut off range in the range of from 200 to 20,000 which forms the lower portion of the solvent reservoir (12); d) drug reservoir (13) comprising a drug-immersed water swellable polymer located below the semipermeable membrane (18); e) patch body (30) comprising an adhesive layer (16) formed around the drug reservoir (13); and f) skin needles (14) fixed vertically in a skin needle plate (15) separated from the patch body. - View Dependent Claims (8, 9, 10, 11, 12, 13)
-
-
14. A transdermal administration method for a peptide drug comprising the steps of:
-
i) contacting the drug immersed in polyelectrolyte with ionizing solvent composition wherein the drug is ionized, ii) forming the drug pathway on the skin epidermis by penetrating a plurality of skin needles into the skin epidermis at a treatment site iii) transferring the ionized drug into the skin at the treatment site by iontophoretic force. - View Dependent Claims (15, 16, 17)
-
-
18. A transdermal administration method for a drug selected from the group consisting of captopril, bradykinin, atriopeptin, calcitonin gene factor, cholecystokinin (CCK-8, 32), β
- -endorphin, nerve growth factor, melanocyte inhibitor -I, gastrin antagonist, neuro-tension, somatotatin, interferon, cyclosporin, encephalins, albumin, insulin, vasopressins, oxytocin, growth hormone, LH (Luetinizing Hormone) and TRH (Thyrotropin Releasing Hormone), comprising the steps of;
i) contacting the drug immersed in a polyelectrolyte with an ionizing solvent composition wherein, the ionizing solvent contains 1 to 50% by volume of solvents selected from the group consisting of salt buffer solutions of phenol derivatives, acetic acid, hydrochloric acid, ammonia water, and caustic soda; and the polyelectrolyte contains 1 to 30% by volume of one or more polyelectrolytes selected from the group consisting of soluble or insoluble polyacrylamide, polyvinylimine, quadravalent ammonium, polyacrylate, carboxymethyl cellulose and alginate, based on 100% by volume of water; ii) forming the drug pathway on the skin by micro-piercing by penetrating a plurality of skin needles into the skin epidermis at a treatment site; and iii) transferring the ionized drug into the skin at the treatment site by iontophoretic force. - View Dependent Claims (19)
- -endorphin, nerve growth factor, melanocyte inhibitor -I, gastrin antagonist, neuro-tension, somatotatin, interferon, cyclosporin, encephalins, albumin, insulin, vasopressins, oxytocin, growth hormone, LH (Luetinizing Hormone) and TRH (Thyrotropin Releasing Hormone), comprising the steps of;
Specification